Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024

Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update

Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024

Anavex Life Sciences Announces Expansion of Leadership Team

Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ

Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update

Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference

Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update

Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders

Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP)

Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update

Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023

Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73)

Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease

Anavex Life Sciences Appoints Senior VP of Regulatory Affairs

Anavex Announces Appointment of Dr Marwan N Sabbagh, MD as Chairman of the Scientific Advisory Board

Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results

Anavex Life Sciences Reports Publication of ANAVEX®3-71

Anavex to Announce Fiscal 2023 Third Quarter Financial Results on Tuesday August 8, 2023